TRADING UPDATES: Beximco s India jab mire; Lamprell gets Aramco deal
Wed, 28th Apr 2021 14:04
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:
Beximco Pharmaceuticals Ltd - Bangladesh-based generic pharmaceutical products and active pharmaceutical ingredients maker - Says agreement with Bangladeshi government and Serum Institute of India Pvt Ltd to deliver 30 million vaccine doses to Bangladesh is hit by India jabs export ban. Does not expect SII to be able to deliver remaining 23 million doses by end of June as India places ban on vaccine exports as cases there surge. The company will collaborate with SII to provide a revised supply schedule once the temporary export controls are relaxed. The expected positive impact on the current financial year, as outlined in the announcement on 5 November 2020, may therefore be mitigated, Beximco says. In addition, Beximco Pharma confirms
Global Covid-19 cases top 146 million
UNB
25th April, 2021 10:41:51
More than 146 million people have been found infected with Covid-19 globally with 3.09 million fatalities on Sunday, according to the Johns Hopkins University (JHU).
The total case count reached at 146, 091,986 while the death toll from the virus climbed to 3,096, 579 as of Sunday.
The US has now surpassed 32 million confirmed cases of Covid-19, according to data collected by Johns Hopkins University.
Coronavirus cases nationwide reached 32,044,976 on Sunday. Covid-19 related deaths now total more than 571,922.
Brazil registered 3,076 more Covid-19-related deaths in the past 24 hours, bringing its death toll to 389,492, the country s Ministry of Health reported on Saturday.
Covid-19: US President Biden needs to help India now
Joe Biden, President, USA - AP×
RELATED
US should share doses from its own supply of Oxford-AstraZeneca, J&J vaccines
India has become the terrifying new epicentre of the Covid-19 pandemic. New cases have topped 300,000 daily and are still rising; the official death toll of over 2,000 per day is almost certainly an underestimate. Every hour brings horrifying new stories of mass cremations, overwhelmed testing centres, people dying while waiting for a hospital bed. The country desperately needs help and the United States (US) should provide it.
To this point, the Biden administration has rebuffed pleas to share the huge US supply of vaccine doses with the rest of the world, making a slight exception only for neighbors Mexico and Canada. And India is hardly the only nation buffeted by a new wave of cases. Brazil’s official death toll is far higher. Many African countries are struggling to procure vaccines, whereas Ind
Published: Apr 23, 2021
Vaccine candidate demonstrates high efficacy at 77% in a study of children aged 5-17 months conducted in Africa
Novavax Matrix-M™ adjuvant used in combination with University of Oxford malaria vaccine candidate, R21, and developed in collaboration with Serum Institute of India
Phase 3 clinical trial to evaluate safety and efficacy begun in 4,800 participants aged 5-36 months
GAITHERSBURG, Md., April 23, 2021 /PRNewswire/
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the pre-print publication of data from a Phase 2b clinical trial in children demonstrating 77 percent efficacy for a malaria vaccine candidate, R21, created by the University of Oxford that includes Novavax Matrix-M™ adjuvant and is licensed to Serum Institute of India (SII). Published online in
E-Mail
Researchers from the University of Oxford and their partners have today reported findings from a Phase IIb trial of a candidate malaria vaccine, R21/Matrix-M, which demonstrated high-level efficacy of 77% over 12-months of follow-up. In their findings (posted on SSRN/Preprints with
The Lancet) they note that they are the first to meet the World Health Organization s Malaria Vaccine Technology Roadmap goal of a vaccine with at least 75% efficacy.
The authors report (in findings in press with
The Lancet) from a Phase IIb randomised, controlled, double-blind trial conducted at the Clinical Research Unit of Nanoro (CRUN) / Institut de Recherche en Sciences de la Santé (IRSS), Burkina Faso. 450 participants, aged 5-17 months, were recruited from the catchment area of Nanoro, covering 24 villages and an approximate population of 65,000 people.